Stock Report

Zydus receives WHO prequalification for Miltefosine formulation and API

Posted On : 2024-02-24 21:32:42( TIMEZONE : IST )

Zydus receives WHO prequalification for Miltefosine formulation and API

Zydus Lifesciences Limited has received the WHO prequalification approval for the API and formulation of the key drug to treat Leishmaniasis, 'Miltefosine'. With this, Miltefosine will be added to WHO's pre-qualification list which will enable larger access to the drug globally.

Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies. The disease affects some of the world's poorest people and is associated with malnutrition, population displacement, poor housing, a weak immune system and lack of financial resources.

According to WHO, there are three main forms of the disease: cutaneous leishmaniasis (CL), visceral leishmaniasis (VL), also known as kala-azar, and mucocutaneous leishmaniasis (MCL). CL is the most common form, VL is the most severe form and MCL is the most disabling form of the disease. VL if left untreated, causes death in more than 90% of cases. An estimated 700 000 to 1 million new cases and an estimated 30 000 new cases of VL occur annually.

In 2018, 92 and 83 countries or territories were considered endemic for, or had previously reported cases of, CL and VL, respectively. Today, more than 1 billion people live in areas endemic for leishmaniasis and are at risk of infection.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 922.10 as compared to the previous close of Rs. 904.80. The total number of shares traded during the day was 82200 in over 3823 trades.

The stock hit an intraday high of Rs. 937.00 and intraday low of 892.60. The net turnover during the day was Rs. 75735994.00.

Source : Equity Bulls


ZydusLifesciences INE010B01027 WHOPrequalification MiltefosineFormulation API